- The minimum inhibitory concentration (MIC) of sulfamethoxazole for a strain of E. coli is 32 µg/mL, and the MIC for trimethoprim is 2 µg/mL. In a checkerboard assay, bacterial growth is inhibited by a combination of 4 µg/mL of sulfamethoxazole and 0.25 µg/mL of trimethoprim. What pharmacological principle does this interaction demonstrate?
Answer: Synergism, as indicated by a fractional inhibitory concentration (FIC) index of 0.25.
The Fractional Inhibitory Concentration (FIC) index is calculated as (MIC of Drug A in combination / MIC of Drug A alone) + (MIC of Drug B in combination / MIC of Drug B alone). In this case, FIC = (4/32) + (0.25/2) = 0.125 + 0.125 = 0.25. An FIC index of ≤ 0.5 indicates synergism, meaning the combined effect of the drugs is significantly greater than the sum of their individual effects. Additivity would result in an FIC index of ~1.0, while antagonism would be > 1.0 (often > 4.0).
- The combination of a sulfonamide and trimethoprim is exceptionally effective due to a mechanism known as sequential blockade. Which statement best describes this principle?
Answer: The drugs inhibit two different enzymes in consecutive steps of the same essential metabolic pathway.
Sequential blockade refers to the inhibition of two or more consecutive steps in a single biochemical pathway. Sulfonamides block dihydropteroate synthase, the first key enzyme. This reduces the production of dihydrofolic acid (DHF). Trimethoprim then blocks the next enzyme, dihydrofolate reductase, which converts DHF to tetrahydrofolic acid (THF). By inhibiting two critical steps in a row, the pathway is much more effectively shut down than by inhibiting either step alone, leading to a synergistic effect.
- Isoniazid (inhibits mycolic acid synthesis) and sulfonamides (inhibit folate synthesis) are both inhibitors of essential metabolic pathways. What is the most fundamental difference between their principles of selective toxicity?
Answer: Isoniazid's target pathway is entirely absent in humans, while sulfonamides' target pathway is present in bacteria but bypassed in humans.
The concept of selective toxicity relies on exploiting differences between the pathogen and the host. The most fundamental difference is the presence or absence of the drug's target pathway. Mycolic acid synthesis is a pathway unique to Mycobacterium and a few related genera; it is completely absent in eukaryotes. In contrast, many bacteria rely on the folate synthesis pathway, but humans do not have this pathway because they obtain folate from their diet (a bypass). While the other statements are largely true (A, B, D), they describe properties of the drugs or the general function of the pathways, not the core reason for their selective toxicity.
- The growth of a susceptible bacterium is completely halted by trimethoprim in a defined minimal medium. Which of the following supplements added to the medium is most likely to restore bacterial growth?
Answer: A mixture of thymidine, purines, and methionine.
Trimethoprim inhibits dihydrofolate reductase, preventing the formation of tetrahydrofolate (THF). THF is essential for donating one-carbon units to synthesize key metabolites. Instead of supplying THF itself (which is often unstable or not transported), growth can be rescued by providing the downstream products that can no longer be synthesized. These include thymidine, purines (adenine, guanine), and certain amino acids like methionine. Providing substrates from earlier in the pathway (A, D) or the direct substrate of the blocked enzyme (B) would be ineffective.
- A bacterial strain possesses a mutated folP gene, resulting in an altered dihydropteroate synthase that confers resistance to sulfamethoxazole. To which of the following antibiotics would this strain most likely exhibit cross-resistance?
Answer: Dapsone
Cross-resistance occurs when a single resistance mechanism confers resistance to multiple drugs. In this case, resistance is due to modification of the target enzyme, dihydropteroate synthase. Therefore, the bacterium will likely be resistant to other drugs that target the same enzyme. Dapsone is a sulfone drug, structurally and mechanistically related to sulfonamides, which also inhibits dihydropteroate synthase. Trimethoprim (A), Ciprofloxacin (B), and Imipenem (D) all have different cellular targets (DHFR, DNA gyrase, and penicillin-binding proteins, respectively) and would not be affected by this specific resistance mechanism.
- The molecular structures of sulfonamide antibiotics are designed to act as competitive inhibitors by mimicking an essential bacterial metabolite. Which molecule's structure is most closely approximated by the sulfonamide core structure?
Answer: Para-aminobenzoic acid
The efficacy of sulfonamides relies on their structural similarity to para-aminobenzoic acid (PABA). PABA is a key substrate for the enzyme dihydropteroate synthase. Because the sulfonamide molecule closely resembles PABA, it can fit into the enzyme's active site, but it cannot be used in the reaction. This competitive binding blocks the true substrate, PABA, from entering, thereby halting the folic acid synthesis pathway. The other options are other intermediates or products in the pathway but are not what sulfonamides mimic.
- A patient being treated with trimethoprim-sulfamethoxazole for a urinary tract infection experiences a relapse. The new bacterial isolate is found to be resistant to the combination therapy. Which genetic event is the most likely explanation for the acquisition of high-level resistance to both drugs simultaneously?
Answer: Acquisition of a transposon carrying genes for both a drug-resistant dihydropteroate synthase and a drug-resistant dihydrofolate reductase.
High-level resistance to the synergistic combination of trimethoprim and sulfamethoxazole typically requires the bacterium to overcome the inhibition of both target enzymes. Acquiring a mobile genetic element, such as a transposon or plasmid, that carries resistant versions of both dihydropteroate synthase (folP) and dihydrofolate reductase (folA) is a common and efficient mechanism for gaining resistance to both drugs at once. A mutation in only one target (A) would not explain resistance to the other drug. While an efflux pump (C) could confer resistance, pumps with dual specificity for these structurally dissimilar drugs are not the primary mechanism. Preventing PABA uptake (D) would be detrimental to the bacterium as it would be unable to synthesize folate, and is not a known resistance mechanism.
- Some bacterial species, like Enterococcus faecalis, exhibit intrinsic resistance to trimethoprim-sulfamethoxazole. The mechanism in many strains involves a gene that encodes a high-affinity folate uptake transporter. How does this system confer resistance?
Answer: It allows the bacterium to utilize pre-formed folate from the host, bypassing the need for the inhibited synthesis pathway.
The basis of sulfonamide and trimethoprim efficacy is that bacteria must synthesize folate de novo, while their hosts (humans) obtain it from their diet. Therefore, bacteria that can acquire an alternative pathway, such as importing pre-formed folate from the host environment via a transporter, can survive even when their internal synthesis pathway is blocked. This bypass mechanism renders the metabolic pathway inhibitors ineffective.
- A researcher performs minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays for sulfamethoxazole (SMX) and trimethoprim (TMP), both alone and in combination. Which set of results is most consistent with the known activity of these agents against a susceptible bacterium?
Answer: SMX: MIC=16, MBC>512; TMP: MIC=1, MBC>64; SMX+TMP: MIC=0.5, MBC=1
Sulfonamides and trimethoprim are typically bacteriostatic when used individually. This is reflected by an MBC that is much higher (often >32-fold) than the MIC. This indicates that the drug inhibits growth but does not kill the bacteria over a wide concentration range. However, when used in combination, the synergistic sequential blockade often results in bactericidal activity. This is reflected by an MBC that is very close to the MIC (typically an MBC/MIC ratio of ≤4). Option B correctly shows high MBC/MIC ratios for the individual drugs and a low MBC/MIC ratio (1/0.5 = 2) for the combination.
- A clinical isolate of Klebsiella pneumoniae shows high-level, plasmid-mediated resistance to trimethoprim. What is the most common mechanism of resistance conferred by such a plasmid?
Answer: A gene for a modified dihydrofolate reductase that has very low affinity for trimethoprim.
When you encounter questions about antibiotic resistance mechanisms, focus on how bacteria actually overcome the drug's intended target rather than assuming complex workarounds.
Trimethoprim works by inhibiting dihydrofolate reductase, an essential enzyme in the folate pathway needed for DNA synthesis. The most common plasmid-mediated resistance mechanism involves producing an alternative version of this enzyme that maintains its normal cellular function but has dramatically reduced binding affinity for trimethoprim. This allows the bacteria to continue folate metabolism even in the presence of the antibiotic, making option D correct.
Option A describes phosphorylation-mediated inactivation, which is a common resistance mechanism for aminoglycosides (like streptomycin) but not for trimethoprim. Trimethoprim resistance doesn't typically involve enzymatic modification of the drug itself.
Option B suggests an alternative metabolic pathway bypassing tetrahydrofolate entirely. This would be metabolically expensive and complex, and such bypass mechanisms aren't the primary mode of trimethoprim resistance. Bacteria typically modify their existing pathways rather than developing entirely new ones.
Option C proposes blocking trimethoprim transport through porin regulation. While transport modification can contribute to resistance, trimethoprim enters cells through general porins rather than specific transporters, making this mechanism less significant than target modification.
Study tip: For antibiotic resistance questions, remember that the most common mechanisms involve modifying the drug's target (like enzymes or ribosomes) rather than complex metabolic rerouting or transport blocking. Target modification is usually the most efficient evolutionary solution.
- A strain of Staphylococcus aureus develops resistance to sulfamethoxazole. Analysis reveals its dihydropteroate synthase enzyme is unchanged, but the intracellular concentration of para-aminobenzoic acid (PABA) is 50 times higher than in the susceptible parent strain. What is the mechanism of resistance?
Answer: The high concentration of the natural substrate, PABA, outcompetes the sulfonamide for the enzyme's active site.
Sulfonamides are competitive inhibitors that act by mimicking PABA and binding to the active site of dihydropteroate synthase. According to the principles of competitive inhibition, the effect of the inhibitor can be overcome by increasing the concentration of the natural substrate. By overproducing PABA, the bacterium ensures that the enzyme is more likely to bind to PABA than to the sulfonamide, thus allowing folic acid synthesis to proceed, leading to resistance.
- A bacteriostatic concentration of a sulfonamide drug is added to a culture of susceptible bacteria. As a direct result of inhibiting dihydropteroate synthase, which downstream process will be the first to be significantly impaired?
Answer: The synthesis of thymidylate and purine nucleotides.
Sulfonamides inhibit the synthesis of folic acid. The active form, tetrahydrofolate (THF), is a crucial coenzyme that donates one-carbon units for the synthesis of essential metabolites. Among the most critical of these are thymidylate (the 'T' in DNA) and purines (the 'A' and 'G' in DNA and RNA). Inhibition of the folate pathway leads directly to a shortage of THF, which in turn halts the production of these necessary DNA precursors, thereby arresting DNA replication and cell division. The other processes are inhibited by different classes of antibiotics (A: aminoglycosides/tetracyclines, C: beta-lactams, D: drugs like daptomycin).
- Dapsone, an inhibitor of dihydropteroate synthase, is a key component of multidrug therapy for leprosy. A new experimental drug is found to be a potent inhibitor of the Mycobacterium leprae dihydrofolate reductase. What is the primary pharmacological rationale for proposing a combination therapy with dapsone and the new drug?
Answer: To achieve a synergistic bactericidal effect through sequential pathway blockade.
When you encounter questions about antimicrobial combination therapy, focus on understanding how different drugs can work together to enhance treatment effectiveness. The key here is recognizing how sequential enzymatic pathway inhibition creates synergistic effects.
Dapsone inhibits dihydropteroate synthase, which catalyzes an early step in bacterial folate synthesis. The experimental drug targets dihydrofolate reductase, which acts later in the same pathway to convert dihydrofolate to tetrahydrofolate. By blocking sequential steps in folate metabolism, these drugs prevent M. leprae from synthesizing essential nucleotides and amino acids needed for DNA replication and cell division. This sequential blockade creates a synergistic bactericidal effect that's more potent than either drug alone, making option A correct.
Option B is wrong because reducing hemolysis isn't achieved through pathway synergy - this would require different mechanisms entirely. Option C incorrectly assumes the combination specifically targets different clinical forms of leprosy, when the mechanism described affects folate synthesis universally in M. leprae. Option D is incorrect because both drugs target the same metabolic pathway active primarily in replicating bacteria, not specifically dormant persister cells, which typically require different therapeutic approaches.
Remember that synergistic drug combinations often work by targeting the same essential pathway at multiple points, creating a "double block" that's harder for bacteria to overcome through resistance mutations. Look for this pattern when evaluating antimicrobial combination therapies - sequential pathway inhibition is a powerful and commonly tested concept.
- Based on these results, what can be concluded about the bacterium's physiology and interaction with the sulfonamide?
Answer: The bacterium synthesizes its own folic acid and lacks an efficient uptake system for exogenous folate.
Growth in Culture 1 shows the bacterium can grow in minimal medium, meaning it synthesizes all essential components, including folic acid. Lack of growth in Culture 2 shows the sulfonamide inhibits this synthesis. Growth in Culture 3 demonstrates that excess PABA can outcompete the sulfonamide (a competitive inhibitor), rescuing growth. The lack of growth in Culture 4 is critical; it shows that even when the final product (folic acid) is provided, the bacterium cannot use it, indicating it lacks a transporter to import it. This is a key aspect of the selective toxicity of folate synthesis inhibitors.
- The enzyme dihydropteroate synthase is competitively inhibited by sulfonamides. When a sulfonamide is added to an actively metabolizing bacterial cell, what is the most immediate molecular consequence at the enzymatic level?
Answer: An accumulation of the substrates PABA and dihydropteroate pyrophosphate.
When you encounter competitive inhibition questions, focus on the immediate, direct effects at the enzyme level rather than downstream consequences. Competitive inhibitors work by competing with the natural substrate for the same binding site on the enzyme.
Sulfonamides are structural analogs of PABA (para-aminobenzoic acid) that compete with PABA for binding to dihydropteroate synthase. When sulfonamide binds to the enzyme instead of PABA, the normal reaction cannot proceed. This means PABA cannot be converted to its product, causing PABA to accumulate along with the other substrate, dihydropteroate pyrophosphate. This makes choice A correct - you see an immediate buildup of substrates that cannot be processed.
Choice B describes a downstream effect that would occur later, not immediately. While THF depletion does happen eventually as the folate synthesis pathway is disrupted, this takes time as existing THF pools are gradually consumed.
Choice C incorrectly describes irreversible inhibition. Competitive inhibition is reversible - sulfonamides don't permanently modify the enzyme; they simply occupy the active site temporarily.
Choice D suggests an allosteric effect on a different enzyme. Dihydrofolate reductase operates later in the pathway and wouldn't experience immediate allosteric changes from competitive inhibition of dihydropteroate synthase.
Remember: competitive inhibition questions test your understanding of immediate versus delayed effects. The most immediate consequence is always substrate accumulation where the block occurs, not the eventual depletion of downstream products.
- A topical sulfonamide is found to be ineffective in treating a skin infection characterized by significant pus formation. In vitro tests confirm the bacterial isolate is highly susceptible to the same sulfonamide. What is the most likely reason for the treatment failure in vivo?
Answer: Cellular debris in the pus provides high levels of PABA, which antagonizes the drug's action.
This is a classic example of environmental antagonism. Pus and necrotic tissue contain breakdown products from lysed host and bacterial cells. Among these products is para-aminobenzoic acid (PABA), the natural substrate that sulfonamides compete with. The high local concentration of PABA in the abscess effectively neutralizes the sulfonamide by outcompeting it for the target enzyme, rendering the drug ineffective despite the bacterium's intrinsic susceptibility.
- A bacterium acquires a mutation in its chromosomal folP gene (dihydropteroate synthase) that confers sulfamethoxazole resistance. Subsequently, it acquires a mutation in its chromosomal folA gene (dihydrofolate reductase) conferring trimethoprim resistance. The double mutant is now resistant to both drugs but grows very slowly and displays a new requirement for thymidine in the growth medium. What does this acquired auxotrophy most likely suggest?
Answer: The mutations conferring drug resistance also severely impaired the normal catalytic efficiency of the respective enzymes.
When you encounter questions about antibiotic resistance mutations coupled with growth defects, think about the trade-offs bacteria face between survival and fitness. This question tests your understanding of how resistance mutations can compromise normal enzyme function.
The key insight here is understanding the folate synthesis pathway. Both folP (dihydropteroate synthase) and folA (dihydrofolate reductase) encode enzymes essential for folate metabolism, which ultimately produces thymidine nucleotides for DNA synthesis. When this bacterium acquired mutations to resist sulfamethoxazole and trimethoprim, it gained survival advantages against these drugs but developed slow growth and thymidine auxotrophy.
This pattern strongly suggests that answer A is correct: the resistance mutations impaired the normal catalytic efficiency of both enzymes. The mutations likely altered active sites enough to prevent drug binding while simultaneously reducing the enzymes' ability to process their natural substrates efficiently. This creates a metabolic bottleneck in thymidine production, explaining why external thymidine supplementation rescues growth.
Answer B is incorrect because the auxotrophy appears linked to the resistance mutations themselves, not off-target effects on thymidylate synthase. Answer C misunderstands the relationship—thymidine isn't inhibiting the enzymes but rather compensating for their reduced function. Answer D incorrectly suggests thymidine neutralizes toxins, when it's actually supplementing deficient metabolic output.
Remember: resistance mutations often come with fitness costs. When you see drug resistance paired with growth defects or nutritional requirements, consider whether the resistance mechanism has compromised normal cellular processes.
- Trimethoprim exhibits excellent selective toxicity against bacteria despite both bacteria and humans possessing a dihydrofolate reductase (DHFR) enzyme. What is the primary molecular basis for this selectivity?
Answer: Trimethoprim binds to the bacterial DHFR with an affinity several thousand-fold higher than to human DHFR.
The basis for trimethoprim's selective toxicity lies in the significant structural differences between the bacterial and human dihydrofolate reductase enzymes. Trimethoprim is specifically designed to fit the active site of the bacterial enzyme far more tightly than the human version. This difference in binding affinity (often >50,000-fold) allows the drug to inhibit the bacterial enzyme at concentrations that have a negligible effect on the human enzyme. Humans do have DHFR and synthesize tetrahydrofolate from dietary folic acid (B). While drug metabolism (D) is a factor in pharmacology, the primary reason for selective toxicity at the molecular level is the differential binding affinity.
- Sulfonamides and trimethoprim are classic examples of metabolic pathway inhibitors. Which statement accurately pairs each drug with the specific enzyme it inhibits?
Answer: Sulfonamides inhibit dihydropteroate synthase; trimethoprim inhibits dihydrofolate reductase.
This question tests the core knowledge of the folate pathway inhibition. Sulfonamides act as competitive inhibitors of dihydropteroate synthase, the enzyme that incorporates PABA into dihydropteroic acid. Trimethoprim acts downstream, inhibiting dihydrofolate reductase, the enzyme that converts dihydrofolic acid (DHF) to the active tetrahydrofolic acid (THF). The most common error is to swap these two targets, as presented in distractor A.
